

References

S-274

Genetic Diseases and Acquired Anemia

1. InterQual® Level of Care Criteria 2021. Acute Care Adult. McKesson Health Solutions, LLC.
2. Arnold SD, Brazauskas R, He N, et al. Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases. *Haematol.* 2017;102(11):1823-1832.
3. Zhang P, Feng K, Xue Y, Zhang C-X, Wang Y, Li X-L. Clinical applications of haploidentical hematopoietic stem cell transplantation in severe aplastic anemia. *Eur Rev Med Pharmacol Sci.* 2017;21(1):155-161.
4. Zhu Y, Gao Q, Hu J, Liu X, Guan D, Zhang F. Allo-HSCT compared with immunosuppressive therapy for acquired aplastic anemia: A system review and meta-analysis. *BMC Immunol.* 2020;21(1):1-11.
5. Iguchi A, Cho Y, Yabe H, et al. Long-term outcome and chimerism in patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation: A retrospective nationwide survey. *Int J Hematol.* 2019;110(3):364-369.
6. Hashem H, Abu AR, Auletta JJ, et al. Successful second hematopoietic cell transplantation in severe congenital neutropenia. *Pediatr Transplant.* 2018;22(1):1.
7. Shadur B, Zaidman I, NaserEddin A, et al. Successful hematopoietic stem cell transplantation for osteopetrosis using reduced intensity conditioning. *Pediatr Blood Cancer.* 2018;65(6):1.
8. Yabe M, Morio T, Tabuchi K, et al. Long-term outcome in patients with Fanconi anemia who received hematopoietic stem cell transplantation: A retrospective nationwide analysis. *Int J Hematol.* 2021;113(1):134-144.
9. Myers K, Hebert K, Antin J, et al. Hematopoietic stem cell transplantation for Shwachman-Diamond syndrome. *Biol Blood Marrow Transplant.* 2020;26(8):1446-1451.

10. Cesaro S, Pillon M, Sauer M, et al. Long-term outcome after allogeneic hematopoietic stem cell transplantation for Shwachman-Diamond syndrome: A retrospective analysis and a review of the literature by the Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation (SAAWP-EBMT). *Bone Marrow Transplant.* 2020;55(9):1796-1809.
11. ElGohary G, El Fakih R, de Latour R, et al. Haploidentical hematopoietic stem cell transplantation in aplastic anemia: A systematic review and meta-analysis of clinical outcome on behalf of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation (SAAWP of EBMT). *Bone Marrow Transplant.* 2020;55(10):1906-1917.
12. Chiesa R, Wang J, Blok HJ, et al. Hematopoietic cell transplantation in chronic granulomatous disease: A study of 712 children and adults. *Blood.* 2020;136(10):1201-1211.
13. Burroughs LM, Petrovic A, Brazauskas R, et al. Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: A PIDTC report. *Blood.* 2020;135(23):2094-2105.

Autoimmune Diseases

14. Malmegrim K, Azevedo J, Amuda L, et al. Immunological balance is associated with clinical outcome after autologous hematopoietic stem cell transplantation in type 1 diabetes. *Front Immunol.* 2017;8:167.
15. Farge D, Arruda L, Brigant F, et al. Long-term immune reconstitution and T cell repertoire analysis after autologous hematopoietic stem cell transplantation in systemic sclerosis patients. *J Hematol Oncol.* 2017;10:21.
16. Muraro PA, Pasquini M, Atkins HL, et al. Long-term outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosis. *JAMA Neurol.* 2017;74(4):459-469.
17. Snowden JA, Sharrack B, Akil M, et al. Autologous haematopoietic stem cell transplantation (aHSCT) for severe resistant autoimmune and inflammatory diseases - A guide for the generalist. *Clin Med (Lond).* 2018;18(4):329-334.
18. Sullivan K, Goldmuntz E, Keyes-Elstein L, et al. Myeloblastic autologous stem-cell for severe scleroderma. *Engl J Med.* 2018;378(1):35-47.

19. Host L, Nikpour M, Calderone A, Cannell P, Roddy J. Autologous stem cell transplantation in systemic sclerosis: A systematic review. *Clin Exp Rheumatol*. 2017;35 Suppl 106(4):198-207.
20. Patel L, Lim YJ, Randomized trials of autologous hematopoietic stem cell transplantation for diffuse cutaneous systemic sclerosis: Systematic review and meta-analysis with trial sequential analysis of overall mortality. 2018;132:612.
21. Muraro PA, Pasquini M, Atkins HL, et al. Long-term outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosis. *JAMA Neurol*. 2017;74(4):459-469.
22. Hayes, Inc. Hayes Health Technology Assessment. *Autologous hematopoietic stem cell transplantation for the treatment of systemic sclerosis*. Lansdale, PA: Hayes, Inc.; 7/19/2019.
23. Sullivan KM, Majhail NS, Bredeson C, et al. Systemic sclerosis as an indication for autologous hematopoietic cell transplantation” position statement from the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. 2018;24:1961-1964.
24. Shouval R, Furie N, Raanani P, Nagler A, Gafter-Gvili A. Autologous hematopoietic stem cell transplantation for systemic sclerosis: A systematic review and meta-analysis. *Biol Blood Marrow Transplant*. 2018;24(5):937-944.
25. Burt RK, Balabanov R, Burman J, et al. Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: A randomized clinical trial. *JAMA*. 2019;321(2):165-174.
26. Sormani MP, Muraro PA, Schiavetti I, et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis. 2017;88(22):2115-2122.
27. Ge F, Lin H, Li A, Chang T. Efficacy and safety of autologous hematopoietic stem-cell transplantation in multiple sclerosis: A systematic review and meta-analysis. *Neurol Sci*, 2019;40(3):479-487.
28. Nash RA, Hutton GJ, Racke MK, et al. High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS. *Neurol*. 2017;88(9):842–852.

29. Leone A, Radin M, Almarzooqi AM, et al. Autologous hematopoietic stem cell transplantation in systemic lupus erythematosus and antiphospholipid syndrome: A systematic review. *Autoimmun Rev.* 2017;16(5):469-477.
30. Leng XM, Jiang Y, Zhou DB, et al. Good outcome of severe lupus patients with high-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation: A 10-year follow-up study. *Clin Exp Rheumatol.* 2017;35(3):494-499.
31. Cao C, Wang M, Sun J, et al. Autologous peripheral blood haematopoietic stem cell transplantation for systemic lupus erythematosus: The observation of long-term outcomes in a Chinese centre. *Clin Exp Rheumatol.* 2017;35(3):500-507.
32. Burt RK, Han X, Gozdzik P, et al. Five year follow-up after autologous peripheral blood hematopoietic stem cell transplantation for refractory, chronic, corticosteroid-dependent systemic lupus erythematosus: Effect of conditioning regimen on outcome. *Bone Marrow Transplant.* 2018;53(6):692-700.
33. M F Silva J, Ladomenou F, Carpenter B, et al. Allogeneic hematopoietic stem cell transplantation for severe, refractory juvenile idiopathic arthritis. *Blood Adv.* 2018;2(7):777-786.
34. Walicka M, Milczarczyk A, Snarski E, et al. Lack of persistent remission following initial recovery in patients with type 1 diabetes treated with autologous peripheral blood stem cell transplantation. *Diabetes Res Clin Pract.* 2018;143:357-363.
35. Lindsay JO, Allez M, Clark M, et al. Autologous stem-cell transplantation in treatment-refractory Crohn's disease: An analysis of pooled data from the ASTIC trial. *Lancet Gastroenterol Hepatol.* 2017;2(6):399-406.
36. Brierley CK, Castilla-Llorente C, Labopin M, et al. Autologous haematopoietic stem cell transplantation for Crohn's disease: A retrospective survey of long-term outcomes from the European Society for Blood and Marrow Transplantation. *J Crohns Colitis.* 2018;29;12(9):1097-1103.
37. Rae-Grant A, Day GS, Marrie RA, et al. Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. *Neurol.* 2018;90(17):789-800.

38. Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. *Neurol.* 2018;90(17):777-788.
39. Cohen JA, Baldassari LE, Atkins HL et al. Autologous hematopoietic cell transplantation for treatment-refractory relapsing multiple sclerosis: Position statement from the American Society for Blood and Marrow Transplantation. *Blood Marrow Transplant.* 2019;25(5).
40. Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. *Ann Rheum Dis.* 2017;76(8):1327-1339.
41. Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG Clinical Guideline: Management of Crohn's Disease in Adults. *Am J Gastroenterol.* 2018;113(4):481-517.
42. Kvistad SAS, Lehmann AK, Trovik LH, et al. Safety and efficacy of autologous hematopoietic stem cell transplantation for multiple sclerosis in Norway. *Mult Scler.* 2020;26(14):1889-1897.
43. Henes J, Oliveira MC, Labopin M, et al. Autologous stem cell transplantation for progressive systemic sclerosis: A prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party. *Haematol.* 2020.
44. van Bijnen S, de Vries-Bouwstra J, van den Ende CH, et al. Predictive factors for treatment-related mortality and major adverse events after autologous haematopoietic stem cell transplantation for systemic sclerosis: Results of a long-term follow-up multicentre study. *Ann Rheum Dis.* 2020;79(8):1084-1089.
45. Burt RK, Balabanov R, Tavee J, et al. Hematopoietic stem cell transplantation for chronic inflammatory demyelinating polyradiculoneuropathy. *J Neurol.* 2020;267(11):3378-3391.
46. Sun SY, Gao Y, Liu GJ, et al. Efficacy and safety of stem cell therapy for T1DM: An updated systematic review and meta-analysis. *J Diabetes Res.* 2020;5740923.

47. Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. *Neurol.* 2020;96(3):114-122.
48. Boffa G, Massacesi L, Inglese M, et al. Long-term clinical outcomes of hematopoietic stem cell transplantation in multiple sclerosis. *Neurology.* 2021;10.1212/WNL.0000000000011461.
49. Burt RK, Han X, Quigley K, Helenowski IB, Balabanov R. Real-world application of autologous hematopoietic stem cell transplantation in 507 patients with multiple sclerosis. *J Neurol.* 2022;269(5):2513-2526.
50. Kanate AS, Majhail NS, Savani BN, et al. Indications for hematopoietic cell transplantation and immune effector cell therapy: Guidelines from the American Society for Transplantation and Cellular Therapy. *Biol Blood Marrow Transplant.* 2020;26(7):1247-1256.